ATMI: Single Use Bioreactors on the Up, but US Tails Europe

Loading the player...

New innovations in single-use bioprocessing systems are being picked up quicker in Europe than in the US, according to ATMI.

in-Pharmatechnologist.com was at ATMI’s facility in Hoegaarden, Belgium to meet Global Product Manager, Eric Isberg and discuss market demand and future innovations in bioreactors and mixing systems.

“If anything, Europe is ahead of the US in terms of innovation and single-use” he said, adding that “maybe if Asia takes on some of this innovation it will push [America] further to become innovative.”

The point was illustrated with ATMI’s Integrity Padreactor, a single-use bioreactor for growing cell cultures, which is cubed rather than cylindrical.

According to Isberg, this ‘square’ reactor can offer better mixing results than traditional ‘round’ tanks yet has not readily been taken up by the US market due to preconceptions based on multi-use stainless-steel systems.

“The square tank was very difficult to clean in the stainless versions,” he said. “Most engineers immediately resist [the square system] because of the cleanability, but of course with single-use you don’t have cleanability issues.”

Global demand for single-use bioreactors is also increasing according to ATMI global sales director Roel Gordijn who told us that although traditional markets still dominate “economies like India, China, Brazil are really picking up now.”

There was some optimism throughout the facility tour and a real belief that single-use bioprocessing solutions would become the standard for the industry. This echoes previous comments that ATMI has said to this publication as ATMI continue to widen its capabilities and offer new innovations to fully integrate the unconventional systems in the biotech world.

Related News

ATMI Adds New Single-Use Tech in Deal with CMO D-Lab

ATMI Adds New Single-Use Fill/Finish Tech in Deal with CMO D-Lab

Tech and Regulatory Issues? Biotech/Manufacturing Firms Discuss

Tech and Regulatory Issues? Biotech/Manufacturing Firms Discuss

ASI and Chromatan talk Single-use at NY Interphex

Customers to Save up to 65% as ASI and Chromatan Pen Single-Use Deal

ATMI: Single-Use Could Replace Multi-Use, as Potency Increases

ATMI: Single-Use Could Replace Multi-Use, as Potency Increases

ATMI Opens US Bio development and testing Lab

ATMI Opens US Bio Development and Testing Lab

Pharma returning West for biomanufacturing partners

BioPharmas That Favour Western CMOs May Soon Look to Asia say Experts

Uptake in Single-Use is Changing Facility Design, Experts Say

Uptake in Single-Use is Changing Facility Design, Experts Say

ATMI invests in Medinstill

ATMI Invests in Medinstill Sterile Fill Tech

Plastic not so fantastic? Single-use systems have their own environmental problems

Plastic not fantastic but single-use is still greener, says industry

Orgenesis completes Belgian facility with a little help from ATMI

Orgenesis and ATMI partner in diabetes cell therapy Belgian subsidiary

Pall to spend $185m on ATMI's Life Science business

ATMI sells bioreactor biz to Pall following strategic review

ATMI starts strategic review

ATMI begins strategic review but says bioreactors business is on track

Pall follows Thermo Fisher, Sartorius trend for single-use tech

Pall follows Thermo Fisher, Sartorius trend for single-use tech

Pall: Single-use skyrockets but stainless steel still shines

Pall: Single-use skyrockets but stainless steel still shines

Integrating single-use into existing facilities still a challenge, says ASI

Janssen's Cork, Ireland facility uses a hybrid system but company calls for standardisation if single-use is set to form part of commercial facility of the future

Biopharma wary of disposable systems for large-scale production... for now

CMO Rentschler doubles capacity with new single-use bioreactor

Rentschler doubles capacity with new single-use bioreactor

Single-use growth outpacing stainless steel, says M&A-hungry Pall

Single-use growth outpacing stainless steel, says acquisition-hungry Pall

Merck Millipore showcases its 2000L Mobius single-use bioreactor in Frankfurt, Germany

Merck Millipore: SMEs choosing single-use to retain manufacturing control

Single-use has been around for over 30 years but the US has always played catch-up with Europe, says report

‘Cautious’ US set to overtake Europe on single-use, says BCC Report

ATMI acquires Artelis in ‘disposables’ deal

ATMI unveils helium integrity testing for bioprocess vessels at Interphex 2011

Single-use drug production tech: ATMI

ATMI gears up for single-use "boom" for biotech industry

ATMI Finesses single-use bioreactors with process control tech deal

ATMI Finesses single-use bioreactors with process control tech deal

Related Products

See more related products